BPC-157 (5mg & 10mg)

Description

Certificate of Analysis

High Performance Liquid Chromatography

Mass Spectrometry

BPC-157 Peptide

The BPC-157 peptide, also known as Pentadecapeptide BPC 157, or Body Protection Compound 157, originated from a protein found in the digestive system, and has been suggested in various studies to assist with healing joint, tendon, and muscle tissue, as well as nerve tissue.

BPC-157 is a peptide composed of 15 amino acids with potential hepatoprotective properties. As the name suggests, Body Protection Compound (BPC) is an amino acid fragment isolated from gastric juice. (1) BPC-157 is also commonly known as pentadecapeptide due to the 15 amino acids it is comprised of. (1)

Overview

BPC-157 has been steadily researched for its potential in wound healing. Presentation of BPC-157 may stimulate the growth hormone (GH) receptors thereby inducing similar GH properties. BPC-157 peptide appears to act by binding with growth hormone receptors, possibly thereby stimulating cell proliferation. This may lead to the development of the new tissue composed of collagen and the development of a network of blood vessels, in a process also called ‘angiogenesis.’ Consequently, the wound is ‘rebuilt’ and healed faster than the usual rate. (1)

BPC-157 has also be studied in correlation to gut health. Serotonin, an enteric neurotransmitter, is localized in the GI tract and GI mucosa. Altered levels of serotonin may inhibit gastric acid secretion, thereby affecting gut mucosal function and influence gastric blood flow. (4) BPC-157 appears to have a particular antidepressant activity, which may counteract the serotonin induced symptoms. The peptide may counteract the 5-HT2A receptors, not allowing the serotonin to bind with these receptors and thereby inhibiting its action. (3) However, as mentioned, the peptide has been researched for its potential action across diverse functions, including:

• Potential in wound healing
• Possible mitigation of pain
• May assist digestive functions
• May encourage normal gut and intestine function
• Possible agent in tendon, ligament, muscle, and bone healing

Multiple studies have since been conducted to understand the full action of the peptide, especially in the area of healing gastrointestinal ulceration, which is elaborated on below. Studies conducted have suggested the peptide to increase the build up of the blood vessels and induce anti-inflammation effects via improving the functional recovery. (5)

Peptide Research and Clinical Studies

BPC-157 Peptide and Wound Healing

In this study, three experimental models of rats were used – first with skin wounds, second with colon anastomosis and third with synthetic sponge implantation. Some of the rats were given a placebo, whereas others were given the BPC 157 peptide. After the study, all models were histologically examined. It was reported by the researchers that the BPC-157 rats appeared to exhibit higher numbers of collagen, reticulin and blood vessel development as compared to the ones given the control placebo. (6)

BPC-157 Peptide and Tendon Healing

This experiment was conducted in the cultured tendon fibroblasts derived from the tendons of rats. The cultures were divided into two groups, one was given a control whereas the other was given BPC-157. Following the study, the following was reported: (1)

• BPC-157 peptide appeared to promote the outgrowth of tendon and tendon healing
• Even under H2O2 stress, BPC-157 appeared to exhibit apparent cell survival under stress
• The peptide appeared to promote migration of the tendon fibroblasts
• BPC-157 reportedly induced apparent increased levels of phosphorylation of both PAK and paxillin, while the total protein level remained unchanged

Upon analysis, it was suggested that the peptide may impact tendon healing, tendon outgrowth and cell survival via the F-actin formation and activation of the FAK and paxillin pathway. (1)

BPC-157 Peptide and Gastrointestinal Healing

This study was conducted to scrutinize the action of BPC-157 peptide against similar angiogenic growth factors such as EGF, FGF and VEGF. The primary assumptions were that BPC-157 is highly stable and biocompatible, and that BPC-157 may be presented by itself. While the study reported improved healing, only BPC-157 was reported to exhibit consistent results in all wound types (i.e. both chronic and acute) on the esophagus, stomach, duodenum, and lower GI tract. This study suggested the extent of the angiogenic potential of the peptide – which appeared to extend not only on local wounds and ligaments, but also on GI wounds and bone healing. (7)

BPC-157 Peptide and Wounds

This study was conducted to understand the extent of the angiogenic potential of the peptide, beyond local wounds, ligaments, and GI tract wounds; and to study its action on multiple gastrointestinal lesions on the pancreas, liver injuries, heart damage, endothelium damage and blood pressure. Following the results, scientists suggested that the BPC-157 peptide may induce a network of activities via peptidergic defense systems.

There are several neurotransmitters and functions considered by scientists to be important, such as dopamine, nitrous oxide, prostaglandin, and other neuron systems. Any over activity or inhibition of these systems may lead to lesions in different organs. BPC-157, through its defense system, appears to counteract with these systems and possibly reverse their over-activation and inhibition. (8)

BPC-157 Peptide and Muscle Healing

This study was conducted on rats with injured gastrocnemius muscle complex. These rats were then presented methylprednisolone (corticosteroid). These corticosteroid rats were then divided into two groups: one group was presented with BPC-157, whereas the other was presented with a placebo. Both compounds were given once in 24 hours and examined at days 1, 2, 4, 7, and 14. Upon examination, it was reported that the corticosteroid appeared to significantly worsen the muscle damage in the rats. However, BPC-157 appeared to exhibit apparent signs of healing and restoration of the damaged gastrocnemius muscle, along with restoring functioning ability. (9)

BPC-157 Peptide and Amphetamine-Induced Hypersensitivity

Laboratory experiments have suggested that the BPC-157 peptide may have the ability to heal multiple different lesions – in GI tract, liver, pancreas, and others. This trend in lab findings indicated that the peptide had some interaction with the dopamine system. To investigate further, this study presented the BPC-157 peptide in amphetamine (dopamine agonist) rats. It was observed that BPC-157 appeared to be able to reverse the amphetamine induced excitability in the rats. Furthermore, rats were presented with another dopamine agonist, haloperidol, and then given amphetamine on days 1, 2, 4 and 10. These rats were then presented with BPC-157 to illustrate its action. Upon examination, it was suggested by the researchers that the peptide appeared to cause an almost complete reversal of the haloperidol action. (10)

BPC-157 Peptide Clinical Trials

BPC 157 has been tested under study PL 14736 in early 2000s. In order to comply with the regulatory requirements, a seven-day trial run was first carried out in rats. In the first clinical trial, 32 male subjected were presented with BPC-157. Upon completion of the trial and physical examination of the test subjects, lab test results and clinical monitoring suggested that the peptide is tolerable. Based on this, it was determined by the researchers that the following double blind, randomized study would be conducted on subjects with ulcerative colitis. Unfortunately, the details on the following study and consecutive results are sparse and not overly informative. (11)(12)(13)

BPC 157 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

 

---

---

 

References:

1. Chang, Chung-Hsun et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of applied physiology (Bethesda, Md. : 1985) vol. 110,3 (2011): 774-80. doi:10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/

2. J.I. Farrell. Contributions to The Physiology of Gastric Secretion. 01 Jul 1928. https://doi.org/10.1152/ajplegacy.1928.85.3.685

3. Sikiric, Predrag et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Current neuropharmacology vol. 14,8 (2016): 857-865. doi:10.2174/1570159×13666160502153022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333585/#r1

4. Ormsbee, H S 3rd, and J D Fondacaro. “Action of serotonin on the gastrointestinal tract.” Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) vol. 178,3 (1985): 333-8. doi:10.3181/00379727-178-42016. https://pubmed.ncbi.nlm.nih.gov/3919396/

5. Krivic, A., Majerovic, M., Jelic, I. et al. Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflamm. res. 57, 205–210 (2008). https://doi.org/10.1007/s00011-007-7056-8

6. S Seiwerth, et al. “BPC 157’s effect on healing.” Journal of physiology, Paris vol. 91,3-5 (1997): 173-8. doi:10.1016/s0928-4257(97)89480-6. https://pubmed.ncbi.nlm.nih.gov/9403790/

7. Seiwerth, Sven et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” Current pharmaceutical design vol. 24,18 (2018): 1972-1989. doi:10.2174/1381612824666180712110447. https://pubmed.ncbi.nlm.nih.gov/29998800/

8. “The pharmacological properties of the novel peptide BPC 157 (PL-10).” Inflammo-pharmacology vol. 7,1 (1999): 1-14. doi:10.1007/s10787-999-0022-z. https://pubmed.ncbi.nlm.nih.gov/17657443/

9. Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, Mise S, Brcic I, Kolenc D, Klicek R, Banic T, Sever M, Kocijan A, Berkopic L, Radic B, Buljat G, Anic T, Zoricic I, Bojanic I, Seiwerth S, Sikiric P. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010 Mar;16(3):BR81-88. PMID: 20190676. https://pubmed.ncbi.nlm.nih.gov/20190676/

10. Jelovac, N et al. “A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.” Biological psychiatry vol. 43,7 (1998): 511-9. doi:10.1016/s0006-3223(97)00277-1. https://pubmed.ncbi.nlm.nih.gov/9547930/

11. Gwyer, D., Wragg, N.M. & Wilson, S.L. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 377, 153–159 (2019). https://doi.org/10.1007/s00441-019-03016-8

12. Veljaca, Marija et al, The development of PL 14736 for treatment of inflammatory bowel disease, Advanced in GI pharmacology, 2002 O-32. https://www.bib.irb.hr/192824

13. Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source. https://clinicaltrials.gov/ct2/show/NCT02637284?

---

Latest Post

Find out more details about this remarkable peptide by reading our latest BPC 157 Review blog post.

NOTE: These products are intended for laboratory research use only. BPC 157 for sale is not for personal use. Please review and adhere to our Terms and Conditions before ordering.